This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

T. F. SCHLAEGEL, Jr., M.D.; LOUIS N. HUNGERFORD, Jr., M.D.

AMA Arch Ophthalmol. 1954;51(4):481-498.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

ISONICOTINIC acid hydrazide, now officially designated isoniazid, was first synthesized in Germany in 1912 as an exercise for a degree in chemistry.¹ Prior to the use of this drug in pulmonary tuberculosis no medical or commercial use was known. Isoniazid was one of over 5,000 drugs tested in vitro and in vivo against Mycobacterium tuberculosis at the Squibb Institute for Medical Research. Isoniazid is marketed under many trade names, among which are Nydrazid, Rimifon, Dinacrin, and INH.*

This report is in three parts: (I) attributes of isoniazid; (II) clinical study of isoniazid in tuberculous uveitis; (III) experimental study of the passage of isoniazid across the blood-aqueous barrier of the rabbit.

I. ATTRIBUTES OF ISONIAZID

Chemistry.

—Isoniazid is a pure, colorless, synthetic crystalline compound which is very soluble in water. The general formula is C₆H₇N₃O and the structural formula:

The close relationship to nicotinic . . . [Full Text PDF of this Article]

Author Affiliations
INDIANAPOLIS

From the Department of Ophthalmology, Indiana University School of Medicine.

Footnotes
Read before the Section on Ophthalmology at the 102nd Annual Meeting of the American Medical Association, New York, June 4, 1953.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?